Technology area: Biotechnology & Pharmaceuticals
5 pending office actions • 5 art units • 5 examiners • 0 of 5 (0%) have an AI response strategy ready • 1 patents granted in the last 365 days
Aim Immunotech Inc. has 5 pending office actions in Biotechnology & Pharmaceuticals. The portfolio is distributed across 5 examiners and 5 art units, indicating that every pending matter has its own identified examination assignment. This structure favors a coordinated docketing process with separate substantive review.
MCLEOD, AFRICA MHAIRIE is the busiest examiner, with 1 pending matter. No examiner or art unit is shown as recurring, so counsel should avoid assuming that an amendment or argument effective in one matter will transfer directly to another. Application-level claim analysis remains central to prosecution management.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §112 only | 2 (40%) |
| Double-patenting + other | 1 (20%) |
| Multi-statute (no §101) | 2 (40%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| MCLEOD, AFRICA MHAIRIE | 1 | 52.8% | +67.7% |
| LEITH, NANCY J | 1 | 74.7% | +44.0% |
| KIM, YUNSOO | 1 | 66.0% | +34.0% |
| CHEN, STACY BROWN | 1 | 66.1% | +40.4% |
| CARTER, SANDRA DILLAHUNT | 1 | 56.2% | +28.6% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17773538 | METHODS, COMPOSITIONS, AND VACCINES FOR TREATING A VIRUS INFECTION | KIM, YUNSOO | — |
| 17179301 | COMPOSITIONS FOR CANCER THERAPY AND METHODS | CARTER, SANDRA DILLAHUNT | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 5 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18685067 | COMPOSITIONS AND METHODS FOR TREATING POST-COVID CONDITIONS OF FATIGUE | MCLEOD, AFRICA MHAIRIE | — |
| 18558498 | METHODS AND COMPOSITIONS FOR TREATING NEUROINFLAMMATION | LEITH, NANCY J | — |
| 17773538 | METHODS, COMPOSITIONS, AND VACCINES FOR TREATING A VIRUS INFECTION | KIM, YUNSOO | — |
| 17621648 | COMPOSITIONS AND METHODS USEFUL FOR EBOLA VIRUS INFECTION | CHEN, STACY BROWN | — |
| 17179301 | COMPOSITIONS FOR CANCER THERAPY AND METHODS | CARTER, SANDRA DILLAHUNT | — |
| Art Unit | Apps |
|---|---|
| 1635 | 1 |
| 1636 | 1 |
| 1641 | 1 |
| 1672 | 1 |
| 1674 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18685067 | COMPOSITIONS AND METHODS FOR TREATING POST-COVID CONDITIONS OF FATIGUE | MCLEOD, AFRICA MHAIRIE | 1635 | §112 | Non-Final OA | — | Pending | Feb 20, 2024 |
| 18558498 | METHODS AND COMPOSITIONS FOR TREATING NEUROINFLAMMATION | LEITH, NANCY J | 1636 | §112 | Non-Final OA | — | Pending | Nov 01, 2023 |
| 17773538 | METHODS, COMPOSITIONS, AND VACCINES FOR TREATING A VIRUS INFECTION | KIM, YUNSOO | 1641 | §103§112Other | Non-Final OA | — | Pending | Apr 29, 2022 |
| 17621648 | COMPOSITIONS AND METHODS USEFUL FOR EBOLA VIRUS INFECTION | CHEN, STACY BROWN | 1672 | §103§112DP | Non-Final OA | — | Pending | Dec 21, 2021 |
| 17179301 | COMPOSITIONS FOR CANCER THERAPY AND METHODS | CARTER, SANDRA DILLAHUNT | 1674 | §102§103Other | Non-Final OA | — | Pending | Feb 18, 2021 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialAim Immunotech Inc. has 5 pending office actions as of October 2026, spread across 5 art units and 5 examiners.
Africa Mhairie Mcleod has the most, with 1 of Aim Immunotech Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
